mAb-话题@MedSci

#mAb#

1302篇内容 | 2335人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1912677, encodeId=e43919126e7a6, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=ARD:评估Taltz(ixekizumab)与阿达木单抗治疗银屑病关节炎患者的疗效和安全性, objectType=article, longId=216821, objectId=a6d72168217e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a6d72168217e, replyNumber=0, likeNumber=68, createdTime=2022-03-26, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a6d72168217e, moduleTitle=ARD:评估Taltz(ixekizumab)与阿达木单抗治疗银屑病关节炎患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a6d72168217e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912641, encodeId=1b1a19126419d, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=协和麒麟mogamulizumab单抗在中国递交上市申请，用于皮肤T细胞淋巴瘤, objectType=article, longId=213745, objectId=e743213e45ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e743213e45ef, replyNumber=0, likeNumber=53, createdTime=2021-10-22, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e743213e45ef, moduleTitle=协和麒麟mogamulizumab单抗在中国递交上市申请，用于皮肤T细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e743213e45ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912658, encodeId=46c71912658f1, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=J Clin Oncol：Tremelimumab 联合Durvalumab治疗不可切除肝细胞癌安全性和疗效：随机I/II期研究, objectType=article, longId=214768, objectId=1da3214e68e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1da3214e68e5, replyNumber=0, likeNumber=76, createdTime=2021-12-29, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1da3214e68e5, moduleTitle=J Clin Oncol：Tremelimumab 联合Durvalumab治疗不可切除肝细胞癌安全性和疗效：随机I/II期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1da3214e68e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912483, encodeId=48de1912483cd, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Gastric Cancer：无论之前是否使用过曲妥珠单抗，nivolumab作为晚期G/GEJ癌患者的三线或后线治疗都是有效和安全的, objectType=article, longId=203354, objectId=409a203354b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=409a203354b2, replyNumber=0, likeNumber=81, createdTime=2021-06-16, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=409a203354b2, moduleTitle=Gastric Cancer：无论之前是否使用过曲妥珠单抗，nivolumab作为晚期G/GEJ癌患者的三线或后线治疗都是有效和安全的, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=409a203354b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912466, encodeId=268119124666e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Lancet Neurology：Galcanezumab对既往2-4类偏头痛预防药物治疗失败的患者的安全性和有效性(CONQUER)：一项多中心、随机、双盲、安慰剂对照的3b期试验, objectType=article, longId=202520, objectId=74bc20252090, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74bc20252090, replyNumber=0, likeNumber=66, createdTime=2021-03-11, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74bc20252090, moduleTitle=Lancet Neurology：Galcanezumab对既往2-4类偏头痛预防药物治疗失败的患者的安全性和有效性(CONQUER)：一项多中心、随机、双盲、安慰剂对照的3b期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74bc20252090)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912559, encodeId=0a8a191255964, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=J Clin Oncol：Pembrolizumab单抗作为晚期非透明细胞肾细胞癌患者一线治疗的开放标签、单臂、II期研究 , objectType=article, longId=207862, objectId=969e20e862ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=969e20e862ea, replyNumber=0, likeNumber=67, createdTime=2021-03-16, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=969e20e862ea, moduleTitle=J Clin Oncol：Pembrolizumab单抗作为晚期非透明细胞肾细胞癌患者一线治疗的开放标签、单臂、II期研究 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=969e20e862ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912622, encodeId=1c221912622cb, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Blood：sutimlimab疗法改善了冷凝集素病的严重溶血性贫血状况, objectType=article, longId=212695, objectId=b3da212695ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3da212695ff, replyNumber=0, likeNumber=57, createdTime=2021-10-25, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3da212695ff, moduleTitle=Blood：sutimlimab疗法改善了冷凝集素病的严重溶血性贫血状况, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b3da212695ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912534, encodeId=cee5191253417, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=珀金埃尔默的Horizon Discovery CHOSOURCE细胞系支持泰诺麦博开发世界**进入临床试验的破伤风毒素mAb药物, objectType=article, longId=206909, objectId=b7b020690985, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7b020690985, replyNumber=0, likeNumber=55, createdTime=2021-07-03, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7b020690985, moduleTitle=珀金埃尔默的Horizon Discovery CHOSOURCE细胞系支持泰诺麦博开发世界**进入临床试验的破伤风毒素mAb药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b7b020690985)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912596, encodeId=846619125960f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=JCO：Pembrolizumab 联合Ipilimumab治疗PD1/PDL1抑制剂失败黑素色瘤的疗效和安全性, objectType=article, longId=211042, objectId=63df21104261, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63df21104261, replyNumber=0, likeNumber=80, createdTime=2022-04-10, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63df21104261, moduleTitle=JCO：Pembrolizumab 联合Ipilimumab治疗PD1/PDL1抑制剂失败黑素色瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63df21104261)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912592, encodeId=d72f191259205, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Nat Med：Durvalumab联合靶向疗法治疗晚期尿路上皮癌, objectType=article, longId=210828, objectId=32fc21082884, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32fc21082884, replyNumber=0, likeNumber=62, createdTime=2021-10-14, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32fc21082884, moduleTitle=Nat Med：Durvalumab联合靶向疗法治疗晚期尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32fc21082884)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912602, encodeId=7a89191260202, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Lancet oncol：Enfortumab vedotin用于抗PD-1治疗后的铂不适用的局部晚期或转移性尿路上皮癌的疗效可期！, objectType=article, longId=211335, objectId=282e211335e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=282e211335e4, replyNumber=0, likeNumber=73, createdTime=2021-10-13, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=282e211335e4, moduleTitle=Lancet oncol：Enfortumab vedotin用于抗PD-1治疗后的铂不适用的局部晚期或转移性尿路上皮癌的疗效可期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=282e211335e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912484, encodeId=3b0c191248496, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Int J Clin Oncol：研究肯定pertuzumab在日本患者中的疗效，支持其在日本患者人群中的继续研究, objectType=article, longId=203356, objectId=48e320335672, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=48e320335672, replyNumber=0, likeNumber=51, createdTime=2021-07-25, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48e320335672, moduleTitle=Int J Clin Oncol：研究肯定pertuzumab在日本患者中的疗效，支持其在日本患者人群中的继续研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=48e320335672)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912678, encodeId=3cf619126e8a3, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Neurology：Occrelizumab在不同类型的多发性硬化症患者中的安全性, objectType=article, longId=216853, objectId=451721685336, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=451721685336, replyNumber=0, likeNumber=98, createdTime=2022-04-22, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=451721685336, moduleTitle=Neurology：Occrelizumab在不同类型的多发性硬化症患者中的安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=451721685336)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912567, encodeId=ea16191256e58, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Prostate：表达AR-V7的转移去势抵抗性前列腺癌中Nivolumab联用ipilimumab以及有无enzalutamide的临床试验, objectType=article, longId=208515, objectId=d0982085157d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d0982085157d, replyNumber=0, likeNumber=62, createdTime=2021-12-06, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d0982085157d, moduleTitle=Prostate：表达AR-V7的转移去势抵抗性前列腺癌中Nivolumab联用ipilimumab以及有无enzalutamide的临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d0982085157d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912443, encodeId=b49a19124436c, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=NEJM：avelumab用于晚期尿路上皮癌患者化疗后的维持治疗, objectType=article, longId=201175, objectId=e4c42011e553, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4c42011e553, replyNumber=0, likeNumber=68, createdTime=2020-12-25, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4c42011e553, moduleTitle=NEJM：avelumab用于晚期尿路上皮癌患者化疗后的维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4c42011e553)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912639, encodeId=15e21912639b7, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Eur Urol：Nivolumab治疗转移性肾细胞癌的患者的原发性肾肿瘤反应 , objectType=article, longId=213725, objectId=ecda213e25ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ecda213e25ad, replyNumber=0, likeNumber=57, createdTime=2022-03-19, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ecda213e25ad, moduleTitle=Eur Urol：Nivolumab治疗转移性肾细胞癌的患者的原发性肾肿瘤反应 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ecda213e25ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912666, encodeId=81ee19126661d, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=JTO:信迪利单抗（Sintilimab）联合培美曲塞+铂类一线治疗局部进展或转移性非鳞状非小细胞肺癌的OS结果更新： 3期临床研究（ORIENT-11）。, objectType=article, longId=215469, objectId=aafc2154691d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aafc2154691d, replyNumber=0, likeNumber=72, createdTime=2022-05-07, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aafc2154691d, moduleTitle=JTO:信迪利单抗（Sintilimab）联合培美曲塞+铂类一线治疗局部进展或转移性非鳞状非小细胞肺癌的OS结果更新： 3期临床研究（ORIENT-11）。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aafc2154691d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912617, encodeId=c944191261e15, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=JAMA Oncol：帕博利珠单抗（Pembrolizumab）联合同步放化疗(cCRT)治疗不可切除的III期NSCLC的疗效和安全性: KEYNOTE-799。, objectType=article, longId=212429, objectId=7a5c212429e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a5c212429e5, replyNumber=0, likeNumber=72, createdTime=2021-08-20, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a5c212429e5, moduleTitle=JAMA Oncol：帕博利珠单抗（Pembrolizumab）联合同步放化疗(cCRT)治疗不可切除的III期NSCLC的疗效和安全性: KEYNOTE-799。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a5c212429e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912453, encodeId=76ba191245348, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Clin Lung Cancer：Atezolizumab可有效治疗日本广泛期小细胞肺癌患者，且耐受性良好, objectType=article, longId=201761, objectId=5d9d201e6149, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d9d201e6149, replyNumber=0, likeNumber=66, createdTime=2021-06-15, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d9d201e6149, moduleTitle=Clin Lung Cancer：Atezolizumab可有效治疗日本广泛期小细胞肺癌患者，且耐受性良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d9d201e6149)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912558, encodeId=faf6191255805, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=JAMA：Blinatumomab可提高首次复发的B细胞急性淋巴细胞白血病高危患儿无事件生存率, objectType=article, longId=207858, objectId=4adc20e8585b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4adc20e8585b, replyNumber=0, likeNumber=60, createdTime=2022-01-04, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4adc20e8585b, moduleTitle=JAMA：Blinatumomab可提高首次复发的B细胞急性淋巴细胞白血病高危患儿无事件生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4adc20e8585b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

mAb

2020-05-29

snf701207 (审核中...)

前往app查看评论内容

#mAb#

ARD:评估Taltz(ixekizumab)与阿达木单抗治疗银屑病关节炎患者的疗效和安全性

2022-03-26

snf701207 (审核中...)

前往app查看评论内容

#mAb#

协和麒麟mogamulizumab单抗在中国递交上市申请，用于皮肤T细胞淋巴瘤

2021-10-22

snf701207 (审核中...)

前往app查看评论内容

#mAb#

J Clin Oncol：Tremelimumab 联合Durvalumab治疗不可切除肝细胞癌安全性和疗效：随机I/II期研究

2021-12-29

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Gastric Cancer：无论之前是否使用过曲妥珠单抗，nivolumab作为晚期G/GEJ癌患者的三线或后线治疗都是有效和安全的

2021-06-16

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Lancet Neurology：Galcanezumab对既往2-4类偏头痛预防药物治疗失败的患者的安全性和有效性(CONQUER)：一项多中心、随机、双盲、安慰剂对照的3b期试验

2021-03-11

snf701207 (审核中...)

前往app查看评论内容

#mAb#

J Clin Oncol：Pembrolizumab单抗作为晚期非透明细胞肾细胞癌患者一线治疗的开放标签、单臂、II期研究

2021-03-16

爆笑小医 (审核中...)

前往app查看评论内容

#mAb#

Blood：sutimlimab疗法改善了冷凝集素病的严重溶血性贫血状况

2021-10-25

snf701207 (审核中...)

前往app查看评论内容

#mAb#

珀金埃尔默的Horizon Discovery CHOSOURCE细胞系支持泰诺麦博开发世界**进入临床试验的破伤风毒素mAb药物

2021-07-03

snf701207 (审核中...)

前往app查看评论内容

#mAb#

JCO：Pembrolizumab 联合Ipilimumab治疗PD1/PDL1抑制剂失败黑素色瘤的疗效和安全性

2022-04-10

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Nat Med：Durvalumab联合靶向疗法治疗晚期尿路上皮癌

2021-10-14

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Lancet oncol：Enfortumab vedotin用于抗PD-1治疗后的铂不适用的局部晚期或转移性尿路上皮癌的疗效可期！

2021-10-13

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Int J Clin Oncol：研究肯定pertuzumab在日本患者中的疗效，支持其在日本患者人群中的继续研究

2021-07-25

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Neurology：Occrelizumab在不同类型的多发性硬化症患者中的安全性

2022-04-22

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Prostate：表达AR-V7的转移去势抵抗性前列腺癌中Nivolumab联用ipilimumab以及有无enzalutamide的临床试验

2021-12-06

snf701207 (审核中...)

前往app查看评论内容

#mAb#

NEJM：avelumab用于晚期尿路上皮癌患者化疗后的维持治疗

2020-12-25

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Eur Urol：Nivolumab治疗转移性肾细胞癌的患者的原发性肾肿瘤反应

2022-03-19

snf701207 (审核中...)

前往app查看评论内容

#mAb#

JTO:信迪利单抗（Sintilimab）联合培美曲塞+铂类一线治疗局部进展或转移性非鳞状非小细胞肺癌的OS结果更新： 3期临床研究（ORIENT-11）。

2022-05-07

snf701207 (审核中...)

前往app查看评论内容

#mAb#

JAMA Oncol：帕博利珠单抗（Pembrolizumab）联合同步放化疗(cCRT)治疗不可切除的III期NSCLC的疗效和安全性: KEYNOTE-799。

2021-08-20

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Clin Lung Cancer：Atezolizumab可有效治疗日本广泛期小细胞肺癌患者，且耐受性良好

2021-06-15

snf701207 (审核中...)

前往app查看评论内容

#mAb#

JAMA：Blinatumomab可提高首次复发的B细胞急性淋巴细胞白血病高危患儿无事件生存率

2022-01-04

科室
- - 订阅+
  - 更多科室
工具
服务